{"schemaVersion":1,"generatedBy":"analyst","note":"Stored Analyst replies for the public demo, generated by scripts/demo-answers.ts: the real Analyst, signed in as the demo viewer, answering each question against the demo fund. Each reply records the model that wrote it. Re-run the script when the snapshot or the questions change.","fallback":"In the product this question would go to the fund's own model with the fund's data behind it. The demo answers from a fixed set of questions instead, so it never spends anyone's API key. Try one of the suggestions, or ask about runway, growth, retention, the pipeline, or a specific company.","suggestions":{"portfolio":["Which companies have less than 12 months of runway?","What's the total unrealized gain across both funds?","Which company grew fastest last year?","Which deals in the pipeline fit our thesis?","What should I follow up on with founders this month?"],"company":{"a67954cb-474b-404b-858b-49c240c22027":["How is NovaTech doing?","What's NovaTech's runway?","Draft a two-sentence NovaTech update for the LP letter"],"b4870bad-ddd4-42d1-a300-7111899cf154":["Is RouteWise ready for a Series C?","How has RouteWise's margin changed?"],"2231479f-1bf3-4646-9173-abc5d31fd515":["Why did TapFin's GMV drop in January?","What is TapFin's take rate?"],"8b396e22-1612-4737-8d09-5dbf593bb08f":["What are the risks with Lattis?","How long until Lattis needs to raise?"],"35dea40d-dd6f-4916-b566-deb40872d579":["How does the DOE grant change Verdant's runway?"],"d1263d61-e648-4906-b991-f831fb74a186":["Compare Benchline and NovaTech on retention","Summarize Benchline's last year"],"d08a27bc-39e4-4fb1-a624-7a286d83e929":["Is AdVantage's churn improving?"],"d4fef540-f26b-426f-9aef-96144a6579ce":["Where is GreenLeaf Bio on the regulatory path?"]}},"answers":[{"scope":"portfolio","question":"Which companies have less than 12 months of runway?","aliases":["runway","who is running out of cash","which companies need to raise soon","cash runway across the portfolio"],"reply":"Based on available cash and burn-rate metrics:\n\nLattis (Pre-Seed): Cash on hand $520K vs. monthly burn $48K (Q4 2025) → roughly 10.8 months of runway. This is the only company clearly under 12 months, and it aligns with its $0 FMV mark, suggesting the position may already be impaired.\n\nClose to the line: Verdant (Seed): $1.1M cash vs. $85K/month burn → ~12.9 months, just above the 12-month threshold but trending down each quarter (burn has risen from $72K to $85K/mo while cash has nearly halved since Q1 2025). Also marked at $0 FMV — worth flagging for a follow-on/bridge or write-off discussion alongside Lattis.\n\nNo runway data available to assess: RouteWise, AdVantage, Benchline, and TapFin don't report a burn rate metric, so runway can't be calculated from what's tracked (though Benchline and RouteWise both look healthy on cash and revenue growth, making runway risk unlikely). GreenLeaf Bio has cash on hand ($1.5M, declining ~$300K/quarter) but no explicit burn figure — if that pace continues, it's roughly 5 quarters out, worth checking directly given its FDA filing timeline in Q2 2026.\n\nRecommend prioritizing Lattis and Verdant for the March 15 portfolio review — both are pre-revenue/early-stage with FMV already marked to zero, and both show sub-13-month runway trending shorter.","model":{"id":"claude-sonnet-5","provider":"anthropic"}},{"scope":"portfolio","question":"What's the total unrealized gain across both funds?","aliases":["unrealized gains","how are the funds marked","portfolio value","total value of the portfolio","fund performance marks"],"reply":"Across Fund I and Fund II combined, total unrealized gain is $28,235,087.50 (total cost of $14,850,000 vs. total fair value of $43,085,087.50), for a blended gross MOIC of 2.9x.\n\nTop contributors: Benchline (+$11.997M), RouteWise (+$9.338M), and TapFin (+$2.953M) drive most of the gain. Verdant and Lattis are marked flat at cost with no unrealized gain (note: portfolio data at top shows Verdant at FMV 0, but the live summary shows it marked at cost/$600K — worth flagging that discrepancy if you're reconciling against another source).","model":{"id":"claude-sonnet-5","provider":"anthropic"}},{"scope":"portfolio","question":"Which company grew fastest last year?","aliases":["fastest growing company","growth across the portfolio","who grew the most in 2025","revenue growth by company"],"reply":"Looking at operating metrics (not just fund marks) for full-year 2025 performance:\n\nNovaTech grew fastest, more than doubling its MRR from $120K (Jan 2025) to $258K (Dec 2025) — a 115% increase over the year, with NRR also climbing steadily from 112% to 121%, indicating healthy expansion alongside new growth.\n\nFor context on other companies with comparable full-year data:\n- Benchline: ARR grew from $7.8M to $10.8M (Q1'25 to Q1'26), +38.5%, still very strong for a Series B at scale.\n- RouteWise: ARR grew from $4.2M to $6.1M over the same period, +45.2%, alongside customer count nearly doubling (42 to 74).\n- GreenLeaf Bio: no revenue yet (pre-FDA clearance), but headcount grew 75% (8 to 14) as it scales for launch.\n\nAdVantage and TapFin only have partial-year data (mid-2025 onward), so a full annual comparison isn't available, but their run-rates (AdVantage MRR +24% in 7 months, TapFin revenue +52% in 7 months) suggest they're also growing quickly.\n\nOn a percentage basis, NovaTech is the standout — it's the smallest of the growth-stage names by revenue, so the 115% jump reflects both real traction and a lower base. If you want \"grew fastest\" measured by absolute dollar growth instead, Benchline ($3M ARR added) and RouteWise ($1.9M ARR added) lead.","model":{"id":"claude-sonnet-5","provider":"anthropic"}},{"scope":"portfolio","question":"Which deals in the pipeline fit our thesis?","aliases":["pipeline","inbound deals","deal flow summary","which deals should we look at","what's in the deals queue"],"reply":"Two inbound deals score \"strong\" thesis fit:\n\n1. Lattice (Marisol Vega) — Vertical SaaS / Agriculture, Seed, raising $3M, sourced via event/Hemrock Partner referral. Status: advancing.\n2. Stellate (Alex Chen) — Developer infrastructure, Series A, raising $5M at $45M post-money, cold inbound. Status: reviewing.\n\nOne additional deal, Haptiq (Fintech infrastructure, Pre-seed, $2.5M raise), is a moderate fit and still marked \"new\" — worth a look but not a clear thesis match.\n\nThe rest are weaker fits: Finch (weak, already passed) and NorthPole Energy (out of thesis, already passed).\n\nRecommend prioritizing Stellate for a closer look given Series A stage and strong fit, and continuing to advance Lattice given the existing referral relationship. Want me to pull the inbound detail on either for founder background and automated research?","model":{"id":"claude-sonnet-5","provider":"anthropic"}},{"scope":"portfolio","question":"What should I follow up on with founders this month?","aliases":["follow ups","open items with founders","what's outstanding","action items","what did I promise founders"],"reply":"Based on recent notes and portfolio status, here's what I'd prioritize this month:\n\n1. NovaTech (2.25x MOIC) — Follow up on the Salesforce strategic partnership Sarah mentioned. Get details on scope/timeline; a partnership like this could be a value inflection point or signal for next-round positioning.\n\n2. RouteWise (3.75x MOIC, your best performer along with Benchline) — Push for specifics on the Series C readiness plan targeting Q3 2026 at $50M+. You'll want traction metrics, runway, and whether they want you to help lead/anchor the round or bring in new investors.\n\n3. GreenLeaf Bio (1.33x MOIC) — Confirm timeline and requirements for the Q2 2026 FDA regulatory filing following the positive pre-submission meeting. Regulatory clearance is a binary catalyst for this one — understand capital needs for the filing process and any bridge financing implications.\n\n4. Verdant and Lattis (both marked at $0 FMV) — These need direct attention. Verdant especially warrants a check-in on runway and viability given the full markdown. For Lattis, the NeurIPS presentation and GitHub traction (5K stars) are good signals — worth probing whether this translates into enterprise pipeline/revenue, since the markdown suggests the fund isn't yet crediting commercial progress.\n\n5. All companies — Q4 financials are due by March 1 ahead of the March 15 portfolio review. Confirm each founder is on track to deliver updated financials, especially Benchline and RouteWise since they're being highlighted in the upcoming LP call.\n\nPriority order: RouteWise (active fundraise), GreenLeaf (regulatory catalyst), then Verdant/Lattis (need triage), then NovaTech (opportunistic upside).","model":{"id":"claude-sonnet-5","provider":"anthropic"}},{"scope":"portfolio","question":"Who are our LPs?","aliases":["list the LPs","limited partners","investors in the fund"],"reply":"We have 7 LP investors across our fund vehicles (Fund I and Fund II):\n\n1. Hemrock Founders Capital LP – $4.0M committed to Fund I, $3.5M to Fund II (our largest LP)\n2. Northstar Family Office (via two entities, I & II LLC) – $3.0M in Fund I, $2.5M in Fund II\n3. Coastal University Endowment – $2.5M in Fund I, $1.5M in Fund II\n4. Greenfield Pension (Greenfield County Employees Pension) – $2.0M in Fund II only\n5. Pinecrest Foundation (Charitable Trust) – $1.5M in Fund I only\n6. Various Angels Fund I (Hemrock Angels Aggregator I LP) – $1.0M in Fund I\n7. Various Angels Fund II (Hemrock Angels Aggregator II LP) – $0.5M in Fund II\n\nTotal commitments: roughly $18M in Fund I and $10M in Fund II. Hemrock Founders Capital is the anchor LP in both vehicles; Coastal University Endowment and Northstar Family Office are the other cross-fund investors, while Greenfield Pension, Pinecrest Foundation, and the two Angels Aggregators participate in a single fund each.","model":{"id":"claude-sonnet-5","provider":"anthropic"}},{"scope":"portfolio","question":"Compare Benchline and NovaTech on retention","aliases":["retention comparison","net revenue retention","NRR vs NDR","which company has the best retention"],"reply":"Retention comparison:\n\nBenchline (Series B) — Net Dollar Retention: 125% (Q1'25) → 128% → 130% (Q3'25 peak) → 127% (Q4'25)\nNovaTech (Series A) — Net Revenue Retention: 112% (Q1'25) → 115% → 118% → 121% (Q4'25, steadily rising)\n\nKey takeaways:\n1. Benchline runs materially higher in absolute terms (127-130% vs. NovaTech's 112-121%), consistent with a more mature Series B enterprise product where expansion revenue from existing accounts is a bigger lever.\n2. Trend direction differs: NovaTech's NRR has climbed every quarter with no reversals — a positive signal that customer success/expansion motion is still improving as the company scales. Benchline's NDR peaked in Q3 2025 (130%) and pulled back 3 points in Q4 (127%), the first deceleration in the series — worth flagging to the team given it coincides with cash burn (14.0M down from 18.0M) and headcount growth; may be worth asking Benchline's team what drove the Q4 softening.\n3. Both remain well above the 100-110% range considered healthy for growth-stage SaaS, so neither is a red flag on its own — but NovaTech's trajectory is the stronger \"still improving\" story, while Benchline's is \"very strong but flattening.\"\n\nGiven RouteWise is prepping a Series C narrative and Benchline is a top-2 LP highlight this cycle, I'd suggest getting a Q1 2026 NDR read from Benchline before the March 15 review to confirm whether the Q4 dip was a blip or a trend.","model":{"id":"claude-sonnet-5","provider":"anthropic"}},{"scope":"portfolio","question":"Summarize the portfolio","aliases":["portfolio summary","how is the portfolio doing","give me an overview","state of the portfolio","portfolio overview"],"reply":"Portfolio Summary (8 active positions)\n\nTotal invested: ~$14.85M\nTotal FMV: ~$42.24M\nBlended MOIC: ~2.84x\n\nStandout performers:\n- Benchline (Series B): 4.00x MOIC, $16.0M FMV on $4.0M invested — largest value driver in the book.\n- RouteWise (Series B): 3.75x MOIC, $12.7M FMV on $3.4M invested — board recently signaled Series C readiness, targeting $50M+ valuation in Q3 2026.\n- TapFin (Series A): 2.60x MOIC, solid markup on $1.85M invested.\n- NovaTech (Series A): 2.25x MOIC, $4.5M FMV; also exploring a potential Salesforce partnership worth watching.\n\nModerate performers:\n- AdVantage (Series A): 1.60x MOIC, steady but unremarkable.\n- GreenLeaf Bio (Seed): 1.33x MOIC; FDA pre-submission meeting went well, filing expected Q2 2026 — could be a catalyst.\n\nConcerns / write-downs:\n- Verdant (Seed): $600K invested, FMV $0 — effectively a write-off.\n- Lattis (Pre-Seed): $250K invested, FMV $0 — marked down despite some product traction (5K GitHub stars, NeurIPS visibility); worth a re-check given community momentum.\n\nTakeaway: Performance is bimodal — two Series B names (Benchline, RouteWise) are carrying the bulk of unrealized gains (~$28.7M of the ~$42.2M FMV), while two early-stage bets (Verdant, Lattis) are total losses on paper. Series A cohort is solidly profitable but not homerun-level yet. Upcoming catalysts to track: RouteWise Series C process, GreenLeaf's FDA filing, and NovaTech's potential Salesforce partnership.","model":{"id":"claude-sonnet-5","provider":"anthropic"}},{"scope":"company:a67954cb-474b-404b-858b-49c240c22027","question":"How is NovaTech doing?","aliases":["NovaTech summary","NovaTech update","tell me about NovaTech","NovaTech performance"],"reply":"NovaTech continues to be one of the stronger names in the portfolio, but there are a couple of trend lines worth flagging for the board.\n\nGrowth & retention: MRR grew from $120K (Jan) to $258K (Dec 2025), consistent with the ~115% YoY growth cited in the Q4 update. Net revenue retention has climbed every quarter — 112% (Q1) to 121% (Q4) — which is best-in-class and validates the \"exceptional NRR\" thesis behind the original investment.\n\nCash position — the item that needs attention: Cash on hand has declined every quarter (3.2M → 2.9M → 2.6M → 2.4M), while quarterly burn has crept up from $85K to $95K. The Q4 summary already flagged this trend and recommended monitoring whether the burn increase is buying proportionate growth or is a signal of eroding efficiency. Worth pushing management in the next update for a clearer view of runway (the Q4 note estimated ~7 quarters at current pace) and a burn-multiple/CAC efficiency breakdown before the next round.\n\nReturns: At $2.0M invested ($500K seed + $1.5M Series A) against a $4.5M fair value, NovaTech is marked at 2.25x MOIC — solidly mid-pack among active peers (behind Benchline's 4.0x and RouteWise's 3.75x, ahead of AdVantage's 1.6x and GreenLeaf's 1.33x).\n\nOther note: team flagged a potential Salesforce strategic partnership in discussion — worth a follow-up in the next 1:1 since a partnership of that scale could meaningfully change the growth/burn calculus and possibly justify the elevated spend.\n\nBottom line: strong top-line and retention story, but the burn creep against declining cash warrants a direct question to management on runway and efficiency before the next board meeting.","model":{"id":"claude-sonnet-5","provider":"anthropic"}},{"scope":"company:a67954cb-474b-404b-858b-49c240c22027","question":"What's NovaTech's runway?","aliases":["NovaTech cash","NovaTech burn","how long can NovaTech last","months of runway NovaTech"],"reply":"Based on the latest figures: NovaTech ended Q4 2025 with $2.4M in cash on hand, down from $3.2M in Q1 2025, while quarterly burn has crept up from $85K in Q1 to $95K in Q4. At the current burn pace, that implies roughly 7 quarters (~1.75 years) of runway remaining — consistent with the runway estimate flagged in the last review (3/8/2026).\n\nTwo things worth watching: (1) the burn trend is upward each quarter despite MRR growth, so it's worth confirming whether the increased spend is buying proportional growth acceleration or margin erosion; and (2) cash has declined roughly $800K over four quarters, so if burn continues rising the runway estimate will compress faster than a flat-burn model suggests. Given NRR is strong and climbing (112% to 121% over the year), the underlying business quality supports the spend, but this is a good moment to ask management for a updated 12-18 month cash plan, especially if a next raise isn't imminent.","model":{"id":"claude-sonnet-5","provider":"anthropic"}},{"scope":"company:a67954cb-474b-404b-858b-49c240c22027","question":"Draft a two-sentence NovaTech update for the LP letter","aliases":["LP letter NovaTech","write an update on NovaTech","NovaTech paragraph for the quarterly letter"],"reply":"NovaTech continued its strong growth trajectory in Q4 2025, with MRR reaching $258K (up from $120K in January) and net revenue retention climbing to a best-in-class 121%, underscoring durable product-market fit in the B2B customer success category. The investment remains a standout performer at 2.25x MOIC ($4.5M fair value on $2.0M invested), though we are monitoring a gradual uptick in quarterly burn (~$95K) against a cash position of $2.4M to ensure spending discipline keeps pace with growth.","model":{"id":"claude-sonnet-5","provider":"anthropic"}},{"scope":"company:b4870bad-ddd4-42d1-a300-7111899cf154","question":"Is RouteWise ready for a Series C?","aliases":["RouteWise Series C","should RouteWise raise","RouteWise fundraising","RouteWise readiness"],"reply":"RouteWise shows several positive signals supporting Series C readiness, though a few data points are still missing from what I can access.\n\nGrowth trajectory: ARR grew from $4.2M (Q1 2025) to $6.1M (Q1 2026) — 45% YoY growth, with sequential acceleration each quarter ($4.2M→$4.8M→$5.1M→$5.5M→$6.1M). That's a healthy, consistent growth curve for a Series B company approaching a Series C conversation.\n\nUnit economics: Gross margin has expanded steadily from 62% to 68% over five quarters — a strong trend for a logistics SaaS business and evidence of operating leverage as the platform scales. Customer count grew from 42 to 74 (76% increase), with the Q4 2025 summary noting 8 new retail customers from the logistics-to-retail vertical expansion, which diversifies concentration risk beyond the core enterprise logistics base.\n\nFund performance: RouteWise is currently marked at a 3.75x MOIC ($3.4M invested, $12.7M FMV), among the strongest performers in the portfolio (behind only Benchline's 4.00x), with a gross IRR over 60%. Share price has risen from $1 (Seed) to $12.5 (latest mark), reflecting sustained value creation across three rounds.\n\nBoard signal: Per the Q4 2025 board recap, management presented a Series C readiness plan targeting a Q3 2026 raise at $50M+ valuation, and the investment team flagged this as a discussion item.\n\nCaveats before signing off as IC: the data I have doesn't include burn rate, cash runway, or net revenue retention — all standard Series C diligence items. The prior summary noted the company was \"approaching cash flow breakeven,\" but I don't have a hard runway figure to confirm sufficiency through a Q3 2026 raise process. I'd recommend requesting updated burn/runway and NRR figures from the company before the board finalizes a go/no-go on timing, but on growth, margin, and customer traction alone, RouteWise looks like a credible Series C candidate.","model":{"id":"claude-sonnet-5","provider":"anthropic"}},{"scope":"company:b4870bad-ddd4-42d1-a300-7111899cf154","question":"How has RouteWise's margin changed?","aliases":["RouteWise gross margin","RouteWise unit economics","RouteWise margins"],"reply":"RouteWise's gross margin has steadily expanded over the past year:\n\nQ1 2025: 62%\nQ2 2025: 64%\nQ3 2025: 65%\nQ4 2025: 67%\nQ1 2026: 68%\n\nThat's a 6-point improvement over five quarters, roughly 1-1.5 points per quarter, with no reversals - a clean, consistent trend rather than a one-off jump. This tracks with the ARR growth (from $4.2M to $6.1M over the same period) and likely reflects improving unit economics as the platform scales - better infrastructure utilization, pricing power with enterprise contracts, and/or a richer mix toward higher-margin retail fulfillment revenue as that vertical ramps. The team's Q4 2025 note flagged the business as \"approaching cash flow breakeven as unit economics improve,\" which is consistent with this margin trajectory. Worth confirming in the next update whether the retail fulfillment expansion carries the same or better margin profile as core logistics, since that mix shift could be a swing factor going into the Series C raise.","model":{"id":"claude-sonnet-5","provider":"anthropic"}},{"scope":"company:2231479f-1bf3-4646-9173-abc5d31fd515","question":"Why did TapFin's GMV drop in January?","aliases":["TapFin GMV","TapFin January","TapFin decline","is TapFin slowing down"],"reply":"Based on the data available, GMV fell from $19.5M in December to $18.2M in January 2026 — a decline of about 6.7%, but this follows a seasonal spike. December's $19.5M was itself flagged as \"a seasonal high driven by holiday spending\" in the Q4 2025 summary, so the January pullback looks like a normal post-holiday reversion rather than a structural problem: merchant transaction volumes typically cool after peak holiday retail/mobile money activity.\n\nA few things worth noting for the IC memo:\n- Revenue moved in the same direction ($292K to $273K), consistent with the take rate holding steady — I don't have January's take rate confirmed yet, but if it stayed near 1.5%, this is a pure volume effect, not pricing or mix deterioration.\n- Even with the January dip, GMV is still up materially year-over-year in trend terms (Jul 2025 $12M to Jan 2026 $18.2M), so the sequential drop doesn't break the underlying growth trajectory.\n- I don't have access to TapFin's narrative reporting/updates right now to confirm whether there were market-specific factors (e.g., currency devaluation, a specific merchant cohort pullback, or processing outages) beyond seasonality — worth pinging the company directly for January color before finalizing the memo, especially given the fund's standing note on FX headwinds in core markets.\n\nI'd flag this as monitor, not alarm — but recommend getting the January operating narrative from TapFin before the board conversation to rule out anything beyond seasonal comedown.","model":{"id":"claude-sonnet-5","provider":"anthropic"}},{"scope":"company:2231479f-1bf3-4646-9173-abc5d31fd515","question":"What is TapFin's take rate?","aliases":["TapFin revenue model","TapFin pricing","how does TapFin make money"],"reply":"TapFin's take rate has held steady at 1.5% in both Q3 2025 and Q4 2025, in line with regional benchmarks. Revenue has scaled roughly proportionally with GMV over that period (e.g., Dec 2025: $19.5M GMV to $292K revenue), suggesting no meaningful pricing or mix shift yet.","model":{"id":"claude-sonnet-5","provider":"anthropic"}},{"scope":"company:8b396e22-1612-4737-8d09-5dbf593bb08f","question":"What are the risks with Lattis?","aliases":["Lattis risk","Lattis concerns","problems with Lattis","Lattis status"],"reply":"Key risks for Lattis (Pre-Seed, Fund II, $250K invested 8/15/24):\n\n1. Tightening runway with rising burn: Cash has fallen from $900K (Q1'25) to $520K (Q4'25) while monthly burn has climbed from $38K to $48K over the same period — a 42% cash decline against a 26% burn increase. At the current $48K/month burn, that's roughly 10-11 months of runway left, and the trend line (burn accelerating, cash depleting) suggests a bridge or priced round will likely be needed within the year.\n\n2. Flat valuation, no markup: The position is still held at cost (1.0x MOIC, $250K FMV) since the initial round — no follow-on financing has validated a step-up yet. For a pre-seed AI infra company approaching a year post-investment, this is worth watching for signs of stalled fundraising momentum.\n\n3. Monetization unclear: Traction cited (5K+ GitHub stars, NeurIPS visibility) is community/open-source engagement, not revenue or paying-enterprise metrics. Open-source vector embedding frameworks often struggle to convert developer adoption into a commercial motion — no ARR or customer data has been reported to assess this.\n\n4. Key-person concentration: Elena Vasquez is the sole named founder; her NeurIPS presentation is good visibility but also underscores reliance on a single technical/founder voice for credibility and fundraising.\n\n5. Competitive/crowding risk: Vector embedding/RAG infrastructure is a crowded, fast-moving space (open-source and well-funded incumbents); sustained differentiation will matter for the next raise given no revenue moat yet reported.\n\nRecommend flagging runway (item 1) as the most time-sensitive — worth a direct check-in with Elena on fundraising timeline and whether GitHub/NeurIPS momentum is translating into term sheets.","model":{"id":"claude-sonnet-5","provider":"anthropic"}},{"scope":"company:8b396e22-1612-4737-8d09-5dbf593bb08f","question":"How long until Lattis needs to raise?","aliases":["Lattis runway","Lattis cash","when does Lattis run out of money"],"reply":"At current burn ($48K/month as of Q4 2025) against $520K cash on hand, Lattis has roughly 10.8 months of runway — implying a cash-out around Q3 2026 if spending holds flat.\n\nHowever, burn has been climbing every quarter (38K → 42K → 45K → 48K, roughly +3-4K/quarter), so flat-burn math is optimistic. If that trend continues, effective runway is shorter, likely closer to 8-9 months, pushing the real fundraise trigger into Q2 2026.\n\nTwo flags for the IC: the fund has already marked this position to $0 FMV (MOIC 0.00x) despite the company being operationally active (5K GitHub stars, NeurIPS visibility), so there's a disconnect between the write-down and the qualitative traction — worth revisiting the valuation. Given the tightening cash position, I'd recommend flagging Lattis for a check-in on fundraising plans now rather than waiting until sub-6-months runway, especially since no revenue/ARR data has been reported to help support a bridge or priced round narrative.","model":{"id":"claude-sonnet-5","provider":"anthropic"}},{"scope":"company:35dea40d-dd6f-4916-b566-deb40872d579","question":"How does the DOE grant change Verdant's runway?","aliases":["Verdant runway","Verdant grant","Verdant cash","Verdant DOE"],"reply":"Verdant's cash position has been declining steadily — $1.8M (Q1) → $1.55M (Q2) → $1.3M (Q3) → $1.1M (Q4 2025) — while monthly burn has crept up from $72K to $85K over the same period. On the current $1.1M cash balance and $85K/month burn, baseline runway is roughly 12.9 months (into Q1 2027) with no further inflows.\n\nThe $200K DOE grant booked in Q4 2025 is a non-dilutive cash inflow that effectively buys back about 2.4 months of runway (200,000 / 85,000/month), pushing the effective run-out date from ~12.9 months to ~15.3 months from Q4. This is consistent with the earlier $150K grant in Q2, which similarly cushioned that quarter's burn — without the two grants ($350K combined), Verdant would have burned through roughly 4+ additional months of cash faster and be sitting notably lower than $1.1M today.\n\nFlag for IC: grant income is helpful but non-recurring and program-dependent — it's not a substitute for revenue growth or a bridge/priced round. With burn trending up (not down) and no grant confirmed for Q1 2026 in the data provided, Verdant's underlying runway problem persists once this grant is absorbed. Worth confirming with the company whether additional DOE tranches or other non-dilutive funding are expected, and whether a bridge is being discussed given cash falls below ~6 months' runway by roughly mid-2026 on current burn trajectory.","model":{"id":"claude-sonnet-5","provider":"anthropic"}},{"scope":"company:d1263d61-e648-4906-b991-f831fb74a186","question":"Summarize Benchline's last year","aliases":["Benchline summary","how is Benchline doing","Benchline update","Benchline performance"],"reply":"Benchline — Trailing Year Summary (Q1 2025 through Q1 2026)\n\nGrowth: ARR climbed from $7.8M (Q1 2025) to $10.8M (Q1 2026), a 38% increase over four quarters. Growth crossed the $10M milestone in Q4 2025 ($10.1M) and continued into Q1 2026, though the pace has moderated — sequential ARR adds were $700K, $700K, $900K, then $700K, indicating steady but not accelerating quarter-over-quarter dollar growth.\n\nRetention: Net dollar retention rose from 125% (Q1 2025) to a peak of 130% (Q3 2025), then pulled back to 127% in Q4 2025 — still excellent by growth-stage SaaS standards, but the deceleration off the Q3 peak is worth watching as a leading indicator on expansion revenue.\n\nHeadcount: Grew from 45 to 62 (+38%) over the year, tracking roughly in line with ARR growth — a reasonable efficiency signal, with hiring concentrated in engineering and customer success per the Q4 2025 update.\n\nCash & Runway: Cash declined steadily from $18.0M to $14.0M over the year (a $4M burn), landing at roughly 18+ months of runway as of Q4 2025. This burn trajectory bears monitoring against the next fundraise timeline, especially if ARR growth continues to decelerate.\n\nQualitative: The network-effects thesis is playing out — Q4 2025 saw 10 new enterprise logos and accelerating inbound interest from PE-backed SaaS companies seeking benchmarking data, validating the core \"moat\" investment rationale.\n\nInvestment Position: Total invested $4.0M (Seed $300K, Series A $1.2M, Series B $2.5M) is now marked at $15.997M FMV, a 4.00x MOIC and ~61% gross IRR — one of the stronger performers in the portfolio (behind only RouteWise at 3.75x among peers of comparable or larger check size, and ahead of NovaTech, AdVantage, and TapFin).\n\nFlag for IC: No update on hand more recent than Q4 2025 commentary despite ARR data through Q1 2026 — worth requesting a fresh operating update to confirm whether the NDR softening and cash burn trend have continued, and to get visibility on runway math against the $10.8M ARR print.","model":{"id":"claude-sonnet-5","provider":"anthropic"}},{"scope":"company:d08a27bc-39e4-4fb1-a624-7a286d83e929","question":"Is AdVantage's churn improving?","aliases":["AdVantage churn","AdVantage retention","AdVantage logo churn","how is AdVantage doing"],"reply":"Yes. AdVantage's logo churn has steadily improved over the last three quarters: 3.5% in Q2 2025, down to 3.2% in Q3 2025, and 2.8% in Q4 2025 — a decline of 70bps over two quarters, roughly a 20% relative reduction.\n\nThis trend is supportive alongside the MRR trajectory: revenue has grown consistently from $280K (Jul 2025) to $348K (Jan 2026), about a 24% increase over seven months. Lower churn combined with steady MRR growth suggests improving retention is contributing to (or at least not offsetting) top-line growth, which is a healthy signal for a Series A AdTech platform at this stage.\n\nOne flag for the board conversation: we only have churn data through Q4 2025 while MRR data extends into Jan 2026. Worth requesting an updated Q1 2026 churn figure to confirm the trend is holding, especially given the elevated MoM MRR growth (Dec to Jan was one of the slower months at +2.4%, versus +4.8% Nov-Dec) — worth probing whether deceleration is linked to any early churn signals not yet reflected in the logo churn metric.","model":{"id":"claude-sonnet-5","provider":"anthropic"}},{"scope":"company:d4fef540-f26b-426f-9aef-96144a6579ce","question":"Where is GreenLeaf Bio on the regulatory path?","aliases":["GreenLeaf FDA","GreenLeaf regulatory","GreenLeaf Bio status","GreenLeaf update"],"reply":"Based on the latest team notes (3/8/2026): GreenLeaf Bio's FDA pre-submission meeting went well, and the team expects to file for regulatory clearance in Q2 2026. That's the most current signal we have on their regulatory path — pre-submission is complete and clearing feedback appears favorable enough that they're proceeding toward a formal filing next quarter.\n\nOne flag for the board conversation: cash on hand has been declining steadily (Q1 2025: $2.4M → Q4 2025: $1.5M) while headcount has grown from 8 to 14 over the same period. If the Q2 2026 regulatory filing timeline slips, runway should be watched closely given the burn trajectory — worth confirming with the company what capital cushion they're planning around the filing and any anticipated clearance-to-revenue gap.","model":{"id":"claude-sonnet-5","provider":"anthropic"}}]}